Merck KGaA (MRCG.DE), has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O), for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.
April 28, 2025 - 15:12
By Pharos Investment Advisors Comments are Off
Merck KGaA (MRCG.DE), has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O), for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved